Runx1 Foundation
Montecito, CA
- UEI
- E9GPPM6RP1G9
- CAGE
- 800X7
- Primary NAICS
- 813211 Grantmaking Foundations
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Tax Exempt)
- Other NAICS codes in SAM.gov
- SAM.gov registration date
- Physical address
- 1482 E Valley Rd #137, Montecito, CA 93108, USA
- Website
- runx1-fpd.org
- Founded
- 2015
- Employees
- 1-10
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Health Care Equipment & Services
- Health Care Providers & Services
- Health & Wellness
- SIC code
- 83 Social Services
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Faseb | Rockville, MD | 813920 Professional Organizations |
| Keystone Symposia On Molecular And Cellular Biology | Silverthorne, CO | 541990 All Other Professional, Scientific, and Technical Services |
| American Society Of Preventive Oncology, Inc. | Indianapolis, IN | — |
| North American Vascular Biology Organization, Inc. | Germantown, MD | — |
| United States Association For The Study Of Pain Inc. | Annapolis, MD | — |
About the company
Runx1 Foundation, a tax-exempt nonprofit based in Montecito, California, serves as a federal grant recipient exclusively — not a federal contractor — receiving National Institutes of Health funding to organize and host annual scientific conferences and patient meetings focused on RUNX1 familial platelet disorder with predisposition to hematologic malignancies (RUNX1-FPD).
The foundation's federal footprint is narrow and specialized. All four awards in the source data are project grants awarded directly to Runx1 Foundation as prime recipient; the foundation does not subcontract on federal grants or contracts. The two funding agencies split evenly: the National Cancer Institute (NCI) has awarded two grants, and the National Center for Advancing Translational Sciences (NCATS) has awarded two. The four awards span 2022 through 2026, with combined obligations of $56 thousand across the period. The most recent award, issued by NCI on May 6, 2026, funds the 10th annual scientific conference and runs through April 30, 2027; one award (the 8th annual conference, awarded by NCI on August 1, 2024) reaches ultimate completion within the next twenty-four months and faces recompete.
Runx1 Foundation's work is patient and investigator convening. Each grant supports an annual in-person or virtual scientific conference and patient meeting designed to foster collaboration, knowledge-sharing, and research presentations among researchers, clinicians, geneticists, patients, and families affected by RUNX1-FPD. The foundation awards travel scholarships to early-career investigators and post-docs to present at poster sessions, operates a Research Guided by Patients Committee (23 members) that provides direct patient input into session planning, and hosts parallel sessions for patients and families alongside research-track programming. Conference attendance has grown from 18 at the 2017 inaugural event to 219–397 participants in recent years. The foundation explicitly prioritizes recruiting underrepresented racial and ethnic groups and women investigators — previous years show over 50% of research attendees were women, 30% were post-docs or graduate students, and 15% of independent investigators were five years or less into their first faculty position.
Quick answers
Is Runx1 Foundation registered in SAM.gov?
Yes. Runx1 Foundation's SAM.gov registration is active through September 9, 2027.
What is Runx1 Foundation's most recent federal award?
Runx1 Foundation's most recent federal grant award is The RUNX1 research program 10TH annual scientific conference and patient meeting (R13CA314280), from National Cancer Institute (NIH), on May 6, 2026.
On GovTribe
See Runx1 Foundation's full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors